Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib + Chemotherapy in Newly Diagnosed FLT3+ AML
NCT02283177Phase 2Completed
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Jan 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crenolanib in acute myeloid leukemia (AML), sponsored by AROG Pharmaceuticals, Inc.. Started Jan 2015; status: completed.
02
Drugs
crenolanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02283177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283177.